ArticleBMC nephrology2026
Efficacy of topical treatment for fungal peritoneal dialysis exit-site infection (ESI).
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis exit site infections (ESIs) is a common complication among patients undergoing peritoneal dialysis (PD). Timely diagnosis and effective treatment are crucial, as they can lead to peritonitis and catheter removal. Although fungal ESIs are rare, they can be particularly harmful, and there are currently no formal recommendations for their management. Eighteen fungal ESI episodes were diagnosed in 11 patients who underwent continuous ambulatory peritoneal dialysis. All initially treated with topical clotrimazole. In 27.7%, oral antifungal therapy was added due to persistent infection. Overall, the treatment success rate was 94%. Importantly, none of the cases progressed and no PD catheters required removal. Fungal ESIs, while rare, can be life-threatening complications for PD patients. Our findings showed that topical antifungal therapy alone was successful in more than 70% of the cases. We achieved complete resolution of ESIs in all patients who completed treatment. Therefore, initial treatment with topical antifungal medication may be a valid approach, provided there is close monitoring. However, further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.